Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mitozantrone Clear all
Completed Phase 2Phase 3 Interventional

Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

NCT00004071
View directory record Official record
Conditions
Prostate Cancer
Interventions
leflunomide, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
3
States / cities
Boca Raton, Florida • Fort Myers, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02728050
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Mitoxantrone, Sorafenib
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 20, 2026, 5:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01342887
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions
cyclosporine, pravastatin sodium, mitoxantrone hydrochloride, etoposide, bone marrow aspiration
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1 Interventional

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

NCT02070458
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
ixazomib, mitoxantrone hydrochloride, etoposide, cytarabine
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 20, 2026, 5:12 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740
View directory record Official record
Conditions
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions
Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

NCT00136084
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute
Interventions
Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
8
States / cities
Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 3 Interventional

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00004001
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine, mitoxantrone, prednisone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
16
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005847
View directory record Official record
Conditions
Prostate Cancer
Interventions
recombinant interferon alfa, estramustine phosphate sodium, isotretinoin, mitoxantrone hydrochloride, paclitaxel, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Denver, Colorado • Atlanta, Georgia • Decatur, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 20, 2026, 5:12 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Mitoxantrone Hydrochloride Liposome Infusion

NCT02856685
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Mitoxantrone Hydrochloride Liposome
Drug
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00004197
View directory record Official record
Conditions
Lymphoma
Interventions
keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy, cyclophosphamide, doxorubicin hydrochloride, mitoxantrone hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Stanford, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1 Interventional

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

NCT01174888
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
midostaurin, Bortezomib, mitoxantrone hydrochloride, etoposide, cytarabine
Drug
Lead sponsor
Alison Walker
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1 Interventional Results available

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

NCT02484391
View directory record Official record
Conditions
Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
Interventions
6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation, Mitoxantrone Hydrochloride
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 20, 2026, 5:12 PM EDT
Terminated Phase 3 Interventional

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

NCT03616470
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Uproleselan, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 20, 2026, 5:12 PM EDT
Terminated Phase 2 Interventional

Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

NCT00183989
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Fludarabine, Mitoxantrone and Rituximab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 20, 2026, 5:12 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

NCT02521493
View directory record Official record
Conditions
Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
Interventions
Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
91 Days to 3 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
169
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1 Interventional Results available

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02303821
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Month to 21 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
22
States / cities
Oakland, California • Orange, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

NCT00512252
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AMD3100, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 20, 2026, 5:12 PM EDT
Not listed Phase 3 Interventional

A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old

NCT03257241
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
A arm (DA-90), B arm (DAC), A arm (CLAG-M), B arm (FLAG-IDA)
Drug
Lead sponsor
Polish Adult Leukemia Group
Other
Eligibility
18 Years to 60 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1 Interventional

Brentuximab Vedotin + Re-induction Chemotherapy for AML

NCT01830777
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Brentuximab Vedotin, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

NCT00546377
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, mitoxantrone hydrochloride, pentostatin, fluorescence in situ hybridization, gene rearrangement analysis, polymerase chain reaction, protein expression analysis, flow cytometry, biopsy
Biological · Drug · Genetic + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 2 Interventional

Use of Topotecan in Patients With Refractory Acute Leukemia

NCT00100477
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Leukemia
Interventions
Topotecan, Mitozantrone, Etoposide
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Sep 20, 2026, 5:12 PM EDT
Terminated Phase 2 Interventional Results available

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

NCT03860844
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Isatuximab, Dexamethasone or equivalent, Fludarabine, Cytarabine, Liposomal daunorubicin, Daunorubicin (nonliposomal), Idarubicin, Filgrastim or equivalent, Mitoxantrone, Doxorubicin, Vincristine, Pegaspargase (PEG) Asparaginase, Cyclophosphamide, Etoposide, Methotrexate, L - Asparginase, Hydroxyurea, L - Asparaginase (Erwinase)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
28 Days to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 20, 2026, 5:12 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab

NCT00208975
View directory record Official record
Conditions
Lymphoma
Interventions
Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 20, 2026, 5:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

NCT01729845
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Kennewick, Washington • Kirkland, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 20, 2026, 5:12 PM EDT